Published On: Wed, Oct 19th, 2016

ITI Inc (NASDAQ:ITCI) – Broker Update

Below are the most recently updated broker updates which include ratings and price targets for ITI Inc (NASDAQ:ITCI).

10/11/2016 – Broker: Piper Jaffray Rating: overweight New Target: 22 reiteration

09/29/2016 – Broker: RBC Capital Rating: outperform New Target: 49 reiteration

09/29/2016 – Broker: SunTrust Rating: neutral New Target: 15 downgrade

09/29/2016 – Broker: JMP Securities Rating: market perform downgrade

09/29/2016 – Broker: Leerink Swann Rating: outperform New Target: 29 reiteration

09/29/2015 – Broker: Guggenheim Rating: buy New Target: 104 reiteration

09/17/2015 – Broker: Ladenburg Thalmann Rating: buy New Target: 75 reiteration

09/17/2015 – Broker: Cowen Rating: outperform New Target: 75 reiteration

The average price target from the most recent broker reports is 52.71

The stock decreased -0.98% (-0.13) during the last days session, reaching 13.12 and roughly 615527 shares were bought or sold by traders. ITI Inc (NASDAQ:ITCI) has decreased by -70.13% over 12 months.

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company’s pipeline includes approximately two product candidates in clinical development and two product candidates in advanced pre-clinical testing. Its platform includes ITI-007 platform and phosphodiesterase (PDE) Inhibitor Platform. It is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances associated with dementia, autism and other CNS diseases. Its ITI-007 platform also includes long acting injectable (LAI) program, and IC200131 program for mood and other disorders. Its PDE Inhibitor Platform includes PDE1 program and PDE2 and PDE9 programs.